viloxazine (Qelbree)
Jump to navigation
Jump to search
Indications
- treatment of attention-deficit hyperactivity disorder (ADHD) in children 6-17 years[1] & adults[2][3]
Contraindications
- concurrent administration of MAO inhibitor (within 14 days)
- pregnancy
Dosage
Capsules: 100, 120 & 200 mg
Dosage adjustment in renal failure
- start 100 mg QD, increase by 50 mg weekly to maximum dose of 200 mg QD for severe renal impairment
Adverse effects
- hypertension
- tachycardia
- mania or hypomania
- somnolence
- fatigue
- nausea/vomiting
- insomnia
- irritability
- potential for suicidal thoughts 7 behaviors, especially within the first few months of treatment or when the dose is changed[1]
Drug interactions
Mechanism of action
More general terms
References
- ↑ 1.0 1.1 1.2 Brooks M FDA Clears Nonstimulant for ADHD in Kids 6 Years and Up. Medscape - Apr 05, 2021. https://www.medscape.com/viewarticle/948727
- ↑ 2.0 2.1 Monaco K FDA OKs New Nonstimulant Option for Adult ADHD/ New selective norepinephrine reuptake inhibitor is no longer just for kids. MedPage Today May 2, 2022 https://www.medpagetoday.com/psychiatry/adhd-add/98504
- ↑ 3.0 3.1 Swift Yasgur B. Nonstimulants: A Better Option for ADHD? Medscape. July 21, 2023 https://www.medscape.com/viewarticle/994659
Price MZ, Price RL Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder. CNS Drugs. 2023. 37:655-660 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37430151 https://link.springer.com/article/10.1007/s40263-023-01023-6 - ↑ Qelbree HIGHLIGHTS OF PRESCRIBING INFORMATION https://www.supernus.com/sites/default/files/Qelbree-Prescribing-Info.pdf